(Q34660887)

3 August 2017

1 reference

title

ZD1839: targeting the epidermal growth factor receptor in cancer therapy (English)

1 reference

3 August 2017

1

Roy S Herbst

1 reference

PubMed ID

12036427

3 August 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

Expert Opinion on Investigational Drugs

3 August 2017

1 reference

3 August 2017

11

1 reference

3 August 2017

837-849

1 reference

3 August 2017

6

1 reference

Kinase inhibitors in cancer therapy: a look ahead

3 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.837

Regulation of signal transduction and signal diversity by receptor oligomerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.837

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.837

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.837

The epidermal growth factor receptor and its inhibition in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.837

Protein kinase inhibitors: the tyrosine-specific protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.837

Tyrosine kinase inhibition: an approach to drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.837

Protein tyrosine kinase inhibitors as novel therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.837

Strategies toward the design of novel and selective protein tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.837

Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.837

Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.837

Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.837

Growth factors and their receptors: new targets for prostate cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.837

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.837

Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interactions with neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.837

10.1517/13543784.11.6.837

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

12036427